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Colorectal cancer (CRC) is one of the leading causes of cancer-related death
worldwide. In order to identify novel prognostic markers or therapeutic targets
for CRC, we searched for candidate genes in our comprehensive gene expression
libraries, and focused on SEC11A, which encodes the SPC18 protein. SPC18 plays
a key role in the endoplasmic reticulum-Golgi secretory pathway and presumably
regulates the secretion of various secretory proteins. An immunohistochemical
analysis of SPC18 in 137 CRC tissue samples demonstrated that 79 (58%) CRC
cases were positive for SPC18. SPC18-positive CRC cases were more advanced in
terms of N classiﬁcation (P = 0.0315) and tumor stage (P = 0.0240) than SPC18-
negative CRC cases. Furthermore, the expression of SPC18 was an independent
prognostic classiﬁer for CRC patients. The cell growth and invasiveness of SPC18
siRNA-transfected CRC cell lines was less than that of the negative control siRNA-
transfected cell lines. The levels of phosphorylated epidermal growth factor
receptor, Erk and Akt were lower in SPC18 siRNA-transfected CRC cells than in
control cells. The expression of SPC18 was colocalized with b-catenin nuclear
localization and MMP7 at the invasive front. An immunohistochemical analysis of
human colorectal polyp specimens revealed a sequential increase in the expres-
sion of SPC18 through the conventional adenoma-carcinoma pathway, while
SPC18 was not expressed or was expressed to a lesser extent in serrated path-
way-related tumors. These results suggest that SPC18 is involved in tumor pro-
gression, and is an independent prognostic classiﬁer in patients with CRC.
C olorectal cancer (CRC) is one of the leading causes ofcancer-related death worldwide.(1) Although the survival
rate of early-stage CRC patients has increased, the long-term
survival rate still remains very poor, mainly due to local
relapse and distant metastases.(2,3) It would be valuable to
identify new therapeutic markers and to supplement standard
clinicopathological staging using molecular markers to more
precisely deﬁne the subset of patients at highest or lowest risk
of recurrence following CRC surgery. In the search for new
therapeutic or diagnostic markers, it is generally accepted that
genes expressed at high levels in tumors and at very low levels
in normal tissues are ideal diagnostic or therapeutic mole-
cules.(4,5) We previously reported that Reg IV, olfactomedin 4,
claudin-18 and h-prune are prognostic makers for CRC.(6–9) In
the present study, we searched for the candidate genes that
met these conditions in our comprehensive gene expression
libraries, and focused on SEC11A, which encodes the SPC18
protein.(10,11) To the best of our knowledge, the expression and
function of SPC18 have not been investigated in human can-
cers with the exception of GC.
SPC18 is one of the subunits of the signal peptidase com-
plex (SPC). SPCs participate in the endoplasmic reticulum
(ER)-Golgi secretary pathway and it is considered that the
overexpression of the SPC18 protein can induce the secretion
of growth factors, including TGF-a.(11–14) TGF-a can phospho-
rylate the epidermal growth factor receptor (EGFR), which
subsequently stimulates multiple signaling pathways involved
in cell proliferation. We investigated the clinicopathological
signiﬁcance and biological function of SPC18 in CRC.
The conventional adenoma-carcinoma pathway and the ser-
rated pathway are considered to be the main colorectal car-
cinogenesis pathways.(15,16) It was reported that the activation
of Wnt/b-catenin signaling occurred via distinct mechanisms
in both pathways.(17) Furthermore, there are several immuno-
histochemical markers that can assist in the conventional mor-
phological diagnosis in tumors that develop via the colorectal
carcinogenesis pathway, including, but not limited to p53, b-
catenin, claudin-18, MLH1 and MSH2.(9,18) In the present
study, we analyzed the signiﬁcance of SPC18 in pre-cancerous
lesions of both colorectal carcinogenesis pathways.
Materials and Methods
Tissue samples and cell lines. In a retrospective study design,
137 primary tumors were collected from patients diagnosed
with CRC who underwent surgery at Hiroshima University
Hospital (Hiroshima, Japan). All patients underwent curative
resection. Only patients without preoperative radiotherapy or
chemotherapy were enrolled in the study. The study population
included 46 men and 87 women. The mean age was 63 years
(range, 29–89 years). Postoperative follow-up was scheduled
every 1, 2 or 3 months during the ﬁrst 2 years after surgery
and every 6 months thereafter, unless more frequent follow-up
was deemed necessary. Chest X-rays, chest computed
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tomography scans and serum chemistry analyses were per-
formed at every follow-up visit. Recurrence was evaluated
from the records at Hiroshima University Hospital. Archival
formalin-ﬁxed, parafﬁn-embedded tissues were used for the
immunohistochemical analysis. The histological classiﬁcations
were determined based on the World Health Organization sys-
tem. Tumor staging was performed according to the TNM
stage grouping system. Ninety-two primary colorectal polyps
were collected from patients who underwent endoscopic or
surgical resection at Hiroshima University Hospital or its afﬁli-
ated hospitals. The distribution of colorectal polyps was as fol-
lows: conventional adenoma low grade (CALG), n = 24
(tubular adenoma, n = 17 and villous or tubulovillous ade-
noma, n = 7); conventional adenoma high grade (CAHG),
n = 29 (tubular adenoma, n = 26 and villous or tubulovillous
adenoma, n = 3); HP (hyperplastic polyp), n = 20, TSA (tra-
ditional serrated adenoma), n = 31; sessile serrated adenoma/
polyp (SSA/P) n = 18 and non-neoplastic mucosa, n = 20.
Written informed consent was not obtained. Thus, for strict
privacy protection, all of the identifying information associated
with the samples was removed before the analysis; this proce-
dure is in accordance with the Ethical Guidelines for Human
Genome/Gene Research that were enacted by the Japanese
Government.
Archival formalin-ﬁxed, parafﬁn-embedded tissues from 137
patients who had undergone the surgical excision of CRC and
from 97 patients who had undergone surgical or endoscopic
resection were used for the immunohistochemical analysis.
The histological classiﬁcations of CRC were based on the
World Health Organization system. Tumor staging was per-
formed according to the TNM stage grouping system.
Human colon cancer-derived cell lines, WiDr, CCK-81,
DLD-1, COLO-201, COLO-320 and LoVo were purchased
from the Japanese Collection of Research Bioresources Cell
Bank (Osaka, Japan). All of the cell lines were maintained in
RPMI 1640 (Nissui Pharmaceutical, Tokyo, Japan) containing
10% fetal bovine serum (FBS, Whittaker, Walkersville, MD,
USA) in a humidiﬁed atmosphere of 5% CO2 and 95% air at
37°C.
Western blotting. Tumor cells were lysed for Western blot-
ting as described previously.(19) The lysates (40 lg) were solu-
bilized in Laemmli sample buffer by boiling and then
subjected to 12% SDS-polyacrylamide gel electrophoresis and
then electrotransferred onto a nitrocellulose ﬁlter. The ﬁlter
was incubated with the primary antibody against SPC18. The
SPC18 antibody was a polyclonal antibody that had been
raised in our laboratory, the speciﬁcity of which has been char-
acterized in detail.(11) Peroxidase-conjugated anti-mouse IgG
was used in the secondary reaction. Immunocomplexes were
visualized with an ECL Western Blot Detection System
(Amersham Biosciences). b-actin antibody (Sigma Chemical,
St. Louis, MO, USA) was also used as a loading control.
Immunohistochemistry. One or two representative tumor
blocks, including the tumor center, invading front, and the
tumor-associated non-neoplastic mucosa, from each patient
were examined by immunohistochemistry. In cases of large,
late-stage tumors, two different sections were examined to
include representative areas of the tumor center as well as of
the lateral and deep tumor invasive front. The immunohisto-
chemical analysis was performed with a Dako Envision+
Mouse Peroxidase Detection System (Dako Cytomation,
Carpinteria, CA, USA). Antigen retrieval was performed by
microwave heating in citrate buffer (pH 6.0) for 30 min.
Peroxidase activity was blocked with 3% H2O2-methanol for
10 min, and the sections were incubated with normal goat
serum (Dako Cytomation) for 20 min to block nonspeciﬁc
antibody binding sites. Sections were incubated with a rabbit
polyclonal anti-SPC18 antibody (dilution 1:50) for 1 h at room
temperature, followed by incubation with Envision+ anti-
mouse peroxidase for 1 h. The sections were incubated with
the DAB Substrate-Chromogen Solution (Dako Cytomation)
for 10 min for the color reaction. The sections were counter-
stained with 0.1% hematoxylin. Negative controls were created
by omission of the primary antibody.
The expression of SPC18 in CRC was scored in all tumors
as positive or negative. When more than 50% of tumor cells
were stained, the immunostaining was considered positive for
SPC18 (according to the median cut off values rounded off to
the nearest 50%). The expression of SPC18 in pre-cancerous
lesions was scored in all tumors as negative (score 0), mild
(score 1), moderate (score 2) or strong (score 3) according to
their immunostaining intensity. The expression of Matrix met-
alloproteinase 7 (MMP7), b-catenin nuclear localization at the
invasive front and p53 was scored in all tumors as positive or
negative. When more than 10% of tumor cells were stained,
the immunostaining was considered to be positive for each
molecule. Using these deﬁnitions, two surgical pathologists
(TH and KS), who had no knowledge of the clinical or patho-
logical parameters, or the patients’ outcomes, independently
reviewed the immunoreactivity of each specimen. Interobserver
differences were resolved by consensus review at a double-
headed microscope after independent review.
RNA interference. To knockdown endogenous SPC18, RNAi
was carried out as described previously.(20) siRNA oligonu-
cleotides for SPC18 and a negative control were purchased
from Invitrogen 3. Transfection was performed using Lipofec-
tamine RNAiMAX (Invitrogen) according to the manufac-
turer’s protocol. Brieﬂy, 60 pmol of siRNA and 10 lL of
Lipofectamine RNAiMAX were mixed in 1 mL of RPMI med-
ium (10 nmol/L ﬁnal siRNA concentration). After 20 min of
incubation, the mixture was added to the cells and these were
plated on dishes for each assay. In all of the experiments, the
cells were analyzed at 48 h after transfection.
Cell growth and in vitro invasion assays. A 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay was performed to examine cell growth.(21) The cells
were seeded at a density of 2000 cells per well in 96-well
plates. Cell growth was monitored after 1, 2 and 4 days. Modi-
ﬁed Boyden chamber assays were performed to evaluate the
invasiveness. The cells were plated at 10 000 cells per well in
RPMI 1640 medium plus 1% serum in the upper chamber of a
Transwell insert (pre diameter, 8 lm; Chemicon, Temecula,
CA, USA) coated with Matrigel. Medium containing 10%
serum was placed in the bottom chamber. After 1 and 2 days,
the cells in the upper chamber were removed by scraping, and
the cells remaining on the lower surface of the insert were
stained with CyQuant GR dye to assess the number of cells.
We performed three different experiments and calculated the
mean and standard deviation (SD) in each of the MTT assays
and the Modiﬁed Boyden chamber assays.
Statistical analysis. Correlations between the clinicopathologi-
cal parameters and the expression of SPC18 were analyzed
using the v2 test. Kaplan–Meier survival curves were con-
structed for SPC18-positive and SPC18-negative patients. The
survival rates of the SPC18-positive and SPC18-negative
groups were compared. Differences between the survival
curves were tested for statistical signiﬁcance by the Log-rank
test. Univariate and multivariate Cox regression analyses were
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used to evaluate the associations between clinical covariates
and survival. The SPSS software program (SPSS Inc., Chicago,
IL, USA) was used for all of the statistical analyses. The haz-
ard ratio (HR) and 95% conﬁdence interval (CI) were esti-
mated from Cox proportional hazard models. Age was treated
as a categorical variable (>65 years vs ≤65 years). All of the
variables that were found to be moderately associated
(P < 0.10) with survival by a univariate analysis were included
in the ﬁnal multivariate Cox regression models. P-values of
< 0.05 were considered to indicate statistical signiﬁcance.
Results
Expression and distribution of SPC18 in CRC and its
relationship with clinicopathological parameters. We used
immunohistochemistry to investigate the expression of SPC18
in 137 human CRC samples. In the non-neoplastic colonic
mucosa, the staining of SPC18 was either weak or absent in
epithelial and stromal cells, whereas corresponding CRC tissue
showed relatively stronger and more extensive staining
(Fig. 1a). SPC18 staining was observed in the cytoplasm of
tumor cells (Fig. 1b). In total, 79 (58%) of the 137 CRC cases
were positive for SPC18. We found that the cancer cells that
robustly expressed SPC18 were preferentially located in the
deeper invasive region of the tumors (Fig. 1c). Next, we ana-
lyzed the relationship between the expression of SPC18 and
various clinicopathological characteristics. SPC18-positive
CRC cases showed a more advanced N classiﬁcation
(P = 0.0315), and tumor stage (P = 0.0240) than SPC18-nega-
tive CRC cases (Table 1). The expression of SPC18 was not
associated with age, sex, M classiﬁcation or budding grade.
The relationship between the expression of SPC18 in CRC and
the prognosis. We performed a Kaplan–Meier analysis to
investigate the association between the expression of SPC18
and the prognosis in order to further elucidate the clinical
impact of SPC18 on CRC in our 137 patients. The expression
of SPC18 was signiﬁcantly associated with a poorer prognosis
(P = 0.0055, Log-rank test, Fig. 1d). Univariate and multivari-
ate Cox proportional hazards analyses were used to further
evaluate the association between the expression of SPC18 and
survival in CRC patients (n = 137, Table 2). In the univariate
analysis, the expression of SPC18 (hazard ratio [HR] 2.74;
95% conﬁdence interval [CI] 1.28–6.50; P = 0.0078), tumor
stage (HR 5.08; 95% CI 2.39–12.04; P < 0.0001) and budding
grade (HR 3.41; 95% CI 1.69–7.31; P = 0.0006) were found
to be associated with survival. We also performed a multivari-
ate analysis using a model that which included the expression
of SPC18, tumor stage and budding grade. The expression of
SPC18 and tumor stage were found to be independent prognos-
tic predictors for survival in CRC patients (HR 2.47; 95% CI
1.06–5.44; P = 0.0336).
Effect of SPC18 inhibition on the cell growth and invasive
activity of CRC cells. We performed a biological study of
SPC18 using CRC cell lines. Western blotting revealed that all
(a) (c)
(b)
(d)
Fig. 1.4 The immunohistochemical analysis of signal
peptidase complex 18 (SPC18) in colorectal cancer
(CRC) tissue specimens. (a) SPC18 immunostaining in
the non-neoplastic colonic mucosa and CRC. SPC18
staining was not observed in the non-neoplastic
colonic mucosa, whereas SPC18 staining was
observed in CRC cells (original magniﬁcation 940).
(b) SPC18 immunostaining in CRC (original
magniﬁcation 9400). SPC18 staining was observed
in CRC cells in the cell cytoplasm. (c) SPC18
immunostaining in CRC (original magniﬁcation
920). SPC18 staining was observed to be stronger
in the deeper invasive region of the tumors of CRC.
(d) Kaplan–Meier plot of the survival of CRC
patients.
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six CRC cell lines expressed SPC18 at various levels (Fig. 2a).
The highest expression of SPC18 was detected in DLD-1 fol-
lowed by LoVo. The other four remaining cell lines had
expressed SPC18 at moderate or low levels. Next, we exam-
ined the transition of the expression of SPC18 by Western
blotting using DLD-1 and LoVo cell lines that had been trans-
fected with three SEC11A-speciﬁc siRNAs (siRNA1, 2, and 3)
because the highest expression of SPC18 was detected in both
of these cell lines (Fig. 2b). The expression of the SPC18 pro-
tein in DLD-1 and LoVo was strongly suppressed by treatment
with siRNA 1 and 3. Thus, we used siRNA1 and 3 in the fol-
lowing experiments to knockdown the endogenous SPC18. To
investigate the possible anti-proliferative effects of SPC18
knockdown, we performed an MTT assay at 4 days after the
transfection of siRNA. The viability of the SPC18 siRNA1 and
the 3-transfected DLD-1 cells was signiﬁcantly in comparison
to negative control siRNA-transfected DLD-1 cells (Fig. 2c).
We performed the same assay in LoVo cells, and similar
results were obtained (Fig. 2d). Next, we performed a tran-
swell invasion assay to determine the possible role of SPC18
in the invasiveness of CRC cells (Fig. 2e,f). On day 2, the
invasiveness of both DLD-1 and LoVo with SPC18
knockdown was <30% that of the negative control siRNA-
transfected DLD-1 cells.
Effect of SPC18 inhibition on the phosphorylation of EGFR,
AKT and ERK in CRC cells. We hypothesized that decreasing the
SPC18 activity through SEC11A knockdown could reduce the
secretion of TGF-a because we previously revealed that
SPC18 contributes to the progression of GC via the secretion
of TGF-a.(11) It is well-known that TGF-a can phosphorylate
the EGF receptor (EGFR), which subsequently stimulates the
multiple signaling pathways involved in cellular proliferation,
anti-apoptosis and other processes, including the Ras-Mek-Erk
and Akt-PI3k pathways.(22,23) To conﬁrm the SPC18-induced
activation of EGFR signaling in CRC, we analyzed the phos-
phorylation of EGFR, Akt and Erk in CRC cells with SPC18
inhibition. The levels of phosphorylated EGFR, Erk and Akt in
the DLD-1 and LoVo cells transfected with SPC18 siRNA1 or
SPC18 siRNA3 were lower than that with negative control
siRNA (Fig 3a,b). These data suggest that SPC18 could con-
tribute to tumor progression in CRC.
Analysis of the correlation between the expression of SPC18
and CRC-related molecules. We revealed that SPC18 could con-
tribute to tumor progression in CRC and the distribution of the
expression of SPC18 in the deeper invasive region of tumors.
We next investigated the relationship between the expression of
SPC18 and CRC-related major molecules, including b-catenin
nuclear localization, MMP7 and p53 (Fig. 4a–d). We revealed
that the expression of SPC18 was colocalized with b-catenin
nuclear localization (P = 0.0251) and the expression of MMP7
(P = 0.0218) at the invasive front (Table 3). These data indi-
cated the possibility of a correlation between SPC18 and Wnt/
b-catenin signaling.
The analysis of the expression of SPC18 in pre-cancerous
lesions in each colorectal carcinogenesis pathway. Finally, we
performed an immunohistochemical analysis of SPC18 in 122
human colorectal polyp specimens, including CALG, CAHG,
TSA and SSA/P (Fig. 5a–f). Staining of strong or moderate
intensity was more frequently observed in CAHG than in CALG
(P = 0.0002). There was no signiﬁcant difference between
Table 1. Relationship between SPC18 expression and
clinicopathological characteristics in 137 patients with colorectal
cancer
SPC18 expression
Positive Negative P-value
Age
≤65 37 (56%) 28 NS
>65 42 (58%) 30
Sex
Female 52 (60%) 35 NS
Male 27 (46%) 23
T classiﬁcation
T1/2 24 (50%) 24 NS
T3/4 55 (62%) 34
N classiﬁcation
Negative 40 (50%) 40 0.0315
Positive 39 (68%) 18
M classiﬁcation
Negative 65 (55%) 54 NS
Positive 14 (78%) 4
Tumor stage
Stage I/II 38 (49%) 39 0.0240
Stage III/IV 41 (68%) 19
Location
Right 17 (65%) 9 NS
Left 62 (56%) 49
Budding grade
Low (Grade 1) 46 (56%) 36 NS
High (Grade 2/3) 33 (60%) 22
Histologic classiﬁcation
Well/moderate 77 (59%) 54 NS
Poor/mucinous 2 (33%) 4
P-values were calculated by Fisher’s exact test. NS, not signiﬁcant.
Table 2. Univariate and multivariate analysis of factors inﬂuencing
survival in 137 patients with colorectal cancer
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age
≤65 1 (Reference) NS
>65 1.37 (0.69–2.77)
Sex
Female 1 (Reference) NS
Male 1.27 (0.63–2.73)
Tumor stage
Stage I/II 1 (Reference) <0.0001 1 (Reference) 0.0041
Stage III/IV 5.08 (2.39–12.04) 3.34 (1.44–8.36)
Budding Grade
Low
(Grade 1)
1 (Reference) 0.0006 1 (Reference) NS
High
(Grade 2/3)
3.41 (1.69–7.31) 1.86 (0.87–4.26)
Histlogic classiﬁcation
Well/
moderate
1 (Reference) NS
Poor/
mucinous
1.54 (0.249–5.101)
SPC18 expression
Negative 1 (Reference) 0.0078 1 (Reference) 0.0336
Positive 2.74 (1.28–6.50) 2.47 (1.06–5.44)
P-values were calculated by Fisher’s exact test. NS, not signiﬁcant.
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tubular adenoma component and villous component. Further-
more, the expression of SPC18 was signiﬁcantly stronger in
conventional adenoma-carcinoma pathway-related tumors
(CALG and CAHG) than in serrated pathway related tumors
(HP, TSA and SSA/P) (P < 0.001) (Fig. 5g). Our results imply
that the expression of SPC18 is correlated with the progression
Fig. 2.5 The effects of the inhibition of signal
peptidase complex 18 (SPC18) on cell growth and
invasive activity in colorectal cancer (CRC) cells. (a)
The Western blotting of SPC18 in the cell lysates
from six CRC cell lines. (b) The Western blotting of
SPC18 in cell lysates from DLD-1 and LoVo
transfected with SPC18 siRNA or negative control
siRNA. b-Actin was included as a loading control. (c,
d) The effect of SPC18 knockdown on the cell
growth of DLD-1 (c) and LoVo (d). Cell growth was
assessed by an MTT assay at 1, 2 and 4 days after
seeding on 96-well plates. The mean (bars) and
standard deviation (SD; error bars) of three
independent experiments are shown. (e, f) The
effect of the knockdown of SPC18 on cell invasion
in DLD-1 (e) and LoVo (f) transfected with SPC18
siRNA (siRNA1 and 3) or negative control siRNA
that were incubated in Boyden chambers. After 1
and 2 days, the invading cells were counted. NS,
not signiﬁcant.
Fig. 3.6 The effect of the downregulation of signal
peptidase complex 18 (SPC18) on the epidermal
growth factor receptor (EGFR) signaling pathway.
(a, b) Western blotting of SPC18, EGFR, phospho-
EGFR (pEGFR), Erk1/2, phospho-Erk1/2 (pErk1/2),
Akt, and phospho-Akt (pAkt) in cell lysates from
DLD-1 (a) and LoVo (b) transfected with SEC11A
siRNA or negative control siRNA. b-Actin was
included as a loading control.
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of CRCs that take the conventional adenoma-carcinoma path-
way. We also performed an immunohistochemical analysis of
SPC18 in microsatellite instability-high (MSI-H) CRC, which is
considered to be a serrated pathway related tumor.(24–26) Nota-
bly, the expression of SPC18 was only detected in one (10%) of
10 MSI-H CRC specimens (Fig. 5h). There is a possibility that
SPC18 is involved in the pathogenesis of the conventional ade-
noma-carcinoma pathway-related colorectal tumor rather than
serrated pathway-related colorectal tumors.
Discussion
In the current study, we analyzed the clinicopathological sig-
niﬁcance of SPC18 in CRC. Our immunohistochemical analy-
ses demonstrated that 58% of CRC cases were positive for
SPC18. The distribution of SPC18-positive CRC cells was
more frequently detected in the deeper invasive region of the
tumors. Moreover, the expression of SPC18 was associated
with the N classiﬁcation and tumor stage. The expression of
SPC18 also served as an independent prognostic classiﬁer of
patients with CRC. The histological features of CRC differ
widely from area to area within the same tumor due to tumor
heterogeneity. The most useful clinicopathological features and
molecular signatures, including the budding grade, can be
deduced from the invasive front of the tumor, where the most
transformed and presumably most aggressive cells reside.(27,28)
Although the expression of SPC18 was not signiﬁcantly corre-
lated with the budding grade, SPC18 tended to be observed at
the invasive front. Thus, SPC18 is likely to promote tumor
progression through several secretion proteins, especially at the
invasive region in SPC18 positive cases. Indeed, the expres-
sion of SPC18 was correlated with b-catenin nuclear localiza-
tion and the expression of MMP7.
Previous studies have shown that the increased SPC activity
caused by the overexpression of SPC18 protein induced tumor
progression through the secretion of TGF-a, to phosphorylate
EGFR and stimulate the multiple signaling pathways involved
in cellular proliferation, anti-apoptosis and other pro-
cesses.(11,23,24) The increased expression of TGF-a in colonic
polyps and cancers has also been reported.(29) Indeed, the pre-
sent study showed that the knockdown of SEC11A by RNA
interference inhibited cancer cell proliferation and invasiveness
in CRC cell lines. Moreover, we showed that the levels of phos-
phorylated EGFR and its downstream molecules, including Erk
and Akt, were lower in SPC18 siRNA-transfected CRC cells
than in control cells. It was reported that the phosphorylation of
Erk and Akt results in inhibition of apoptosis and contribute to
tumor progression, including metastasis.(30,31) Thus, these
results suggest that SPC18 participates in malignant behavior,
including the cell growth, metastasis and invasion of CRC cells
via several growth factors, including at least TGF-a.
The main colorectal carcinogenesis pathways are the conven-
tional adenoma-carcinoma pathway and the serrated path-
way.(15,16) The present study demonstrated a sequential increase
in the expression of SPC18 through the conventional adenoma-
carcinoma pathway. The conventional adenoma-carcinoma path-
way is well known as a multistep carcinogenesis mechanism that
is associated with the activation of Wnt/b-catenin signaling.(16,24)
(a) (b)
(c) (d)
Fig. 4. 7The analysis of the correlation between the
expression of signal peptidase complex 18 (SPC18)
and colorectal cancer (CRC)-related molecules in the
invasive front. (a) The expression levels of SPC18 (b–
d) CRC-related molecules, including b-catenin,
Matrix metalloproteinase 7 (MMP7) and p53, were
examined. A serial section showed that the MMP7
and b-catenin nuclear localization at the invasive
front was partially adjacent to the area in which
SPC18 was expressed.
Table 3. Relationship between SPC18 expression and CRC related
molecules at the invasive frontin 137 patients with colorectal cancer
SPC18 expression
Positive Negative P-value
b-catenin (nuclear localization)
Positive 58 (66%) 29 0.0251
Negative 21 (54%) 25
MMP7
Positive 29 (72%) 11 0.0218
Negative 50 (52%) 47
p53 expression
Positive 41 (58%) 29 NS
Negative 38 (56%) 29
P-values were calculated by Fisher’s exact test. NS, not signiﬁcant.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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It is also well known that the activation of Wnt/b-catenin signal-
ing promotes tumor malignancy and induces the expression of
MMP7.(32) In the present study, SPC18 expression was dis-
tributed extensively in the whole tumor and was unexceptionally
observed at the invasive front. Although the relationship between
SPC18 expression and T classiﬁcation was not statistically signif-
icant, SPC18 might contribute to tumor progression. Moreover,
b-catenin nuclear localization was also observed at the invasive
front due to Wnt signaling activation.(33) Co-localization of these
molecules at the invasive front suggests that b-catenin nuclear
localization might activate SPC18 expression as well as Wnt
pathway signaling. A detailed function analysis should be per-
formed using methods such as siRNA-knock down or an in vivo
analysis in order to further our understanding of the relationship
between SPC18, b-catenin and MMP7.
In summary, we revealed that CRC with the expression of
SPC18 was independently associated with a poor prognosis.
SPC18 regulates the phosphorylation of EGFR and modulates
downstream targets. Thus, SPC18 has potential as a therapeutic
target and predictive biomarker for the survival of patients
with CRC.
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Fig. 5.8 The analysis of the expression of signal peptidase complex 18 (SPC18) in pre-cancerous lesions of each colorectal carcinogenesis pathway.
(a–f) The immunostaining of SPC18 in colorectal polyps (CRPs). (a) Conventional adenoma low-grade: tubular adenoma component, n = 17; (b)
Conventional adenoma low-grade: villous component, n = 7 (c) conventional adenoma high-grade (CAHG), n = 29; (d) hyperplastic polyp.
n = 20; (e) traditional serrated adenoma (TSA), n = 31; and (f) sessile serrated adenoma/polyp (SSA/P), n = 18. (g) The SPC18 immunostaining
scores in CRPs. The graph indicates the percentage of sections with different scores (negative, weak, moderate and strong). (h) A representative
image of the expression of SPC18 in MSI-H serrated pathway-related CRC. NS, not signiﬁcant.
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